Italia markets closed

SVB Financial Group (SIVB)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
302,44+6,82 (+2,31%)
Alla chiusura: 04:00PM EST
295,50 -6,94 (-2,29%)
Dopo ore: 07:52PM EST
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente295,62
Aperto293,63
Denaro295,50 x 900
Lettera306,70 x 900
Min-Max giorno292,50 - 305,01
Intervallo di 52 settimane198,10 - 658,47
Volume664.837
Media Volume1.078.000
Capitalizzazione17,896B
Beta (5 anni mensile)1,48
Rapporto PE (ttm)11,90
EPS (ttm)25,42
Prossima data utili20 apr 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendo10 feb 1992
Stima target 1A282,94
  • GlobeNewswire

    Lucira Health Secures Debt Facility of Up to $80 Million from Hercules Capital and Silicon Valley Bank

    EMERYVILLE, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that on February 4, 2022, it entered into a debt facility of up to $80 million with Hercules Capital, Inc. (NYSE: HTGC) ("Hercules") and Silicon Valley Bank (NASDAQ: SIVB) ("SVB"). "This debt financing will provide Lucira l

  • GlobeNewswire

    Tarsus Completes Enrollment for the Pivotal Phase 3 Saturn-2 Trial of TP-03 to Treat Demodex Blepharitis and Secures $175 Million Credit Facility

    Topline data expected in April 2022 from Saturn-2, the second Phase 3 pivotal trial of TP-03 and NDA submission remains on track for this year Credit facility with Hercules Capital and Silicon Valley Bank provides availability of non-dilutive capital IRVINE, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today